Health Care — COVID tests, treatments could soon cost you


The COVID-19 omicron subvariants BQ.1 and BQ.1.1 have pushed the BA.5 subvariant out of its place as the dominant version of the coronavirus in the U.S., eliciting concerns from health experts as vaccine booster uptake remains low and evidence emerges of treatments being less effective.

As of this week, the BA.5 omicron subvariant now accounts for about a quarter of new COVID-19 cases in the U.S., with BQ.1 and BQ.1.1 each making up roughly an equal proportion of infections. These two subvariants are themselves descended of BA.5 and now account for about 48 percent of cases.

For much of 2022, the BA.5 and BA.4 omicron subvariants were the predominant versions of SARS-CoV-2 causing infections. However, the COVID-19 virus continues to mutate, resulting in pathogens that appear to be less susceptible to monoclonal antibodies.

Earlier this month, the Food and Drug Administration (FDA) updated its guidance for the monoclonal antibody bebtelovimab to indicate that BQ.1 and BQ.1.1 showed significant reductions in susceptibility to the treatment.

The FDA similarly revised its guidance for Evusheld, a combination of two monoclonal antibodies, to note significant reduction in susceptibility when it came to BQ.1 and BQ.1.1. This treatment has largely been used for those with compromised immune systems who may not develop a strong enough response after vaccination.

Other treatments like the Pfizer antiviral Paxlovid are expected to still be effective against these newer subvariants, as the drug inhibits a specific enzyme that the COVID-19 virus needs to replicate.

Recent data has indicated that the bivalent COVID-19 booster should also still be effective against them, as the updated shot was designed to specifically build up immunity against BA.5.

Pfizer and BioNTech on Friday said their updated bivalent shot had been found to offer protection against multiple descendants of BA.4 and BA.5 in a preprint study. After a dose of the bivalent shot was administered, the companies said neutralizing antibodies against BQ.1.1 rose by 6.7-fold.

Enthusiasm for the booster has been low, however, with only about 11 percent of eligible individuals opting to get the shot so far. Current case rates for coronavirus have plateaued in recent weeks after having fallen for several months.

You May Also Like

‘Lady in red’ who police sought over Nicola Bulley’s disappearance did not see her

The family of missing mother Nicola Bulley have been dealt a fresh…

Britain would run out of ammo in a day if it fought Russia: Cuts have left military’s stores bare

Britain’s ammo stocks would run out in a day if it fought…

Driver arrested, accused of hit-and-run crash at Aurora bus stop on Jan. 24

AURORA, Colo. — Aurora police announced Thursday that a driver accused of…

Britain’s biggest ever avian flu outbreak infects mammals including otters and foxes

Britain’s biggest outbreak of bird flu has led to infections in mammals…

Pictured: The sympathy card that nurse Lucy Letby wrote to grieving parents

This is the sympathy card that nurse Lucy Letby wrote to the…

Legendary Smiths guitarist Johnny Marr gives lucky schoolboy busker a £1,000 cash grant

Legendary Smiths guitarist Johnny Marr gives lucky schoolboy busker a £1,000 cash…

Cornwall school tells girls to ask for ‘red card pass’ while on period to go to toilets during class

Parents condemn secondary school for a ‘complete lack of privacy’ as it…

Bank of England Hikes Interest Rates Amid Inflation Crisis

LONDON (AP) – The Bank of England raised interest rates by half…